Vancouver, B.C., January 5th. 2021 – SOLARVEST BIOENERGY INC. (TSXV:SVS.VN) (“Solarvest” or the “Company”), is pleased to announce the addition of Greg Drohan to its Board of Directors. Mr. Drohan will join the Board in early 2021.
Mr. Drohan was the past President of Carter-Horner prior to its acquisition by Church & Dwight. He then became President of Church & Dwight Canada Corp for 12 years. As President he successfully merged the Church & Dwight and Carter-Horner businesses to form a larger more profitable business entity, which more than doubled the sales revenue of the company and achieved #1 market share on brands such as Trojans, Oxi Clean, First Response, Rub A535, Arm & Hammer. Mr. Drohan also oversaw the company’s Vitafusion and L’il Critter gummy nutraceutical line of products.
Gerri Greenham, President and CEO of Solarvest says, “Greg has agreed to participate on the Board as well as taking an active role in the commercialization of our Omega-3 line of products. His experience in sales and marketing of national brands will be invaluable as well as his knowledge of the nutraceutical marketplace through Church & Dwight’s line of products which will help steer our marketing plans.” Greg previously served as a Director at Tetra Bio Pharma and on the Alumni Relations Board of Ryerson University. He earned a Bachelor of Business Management degree at Ryerson and holds a Masters Business Administration from York University, Schulich School of Business.
As of December 30th Michael O’Brien has resigned from the Board after a long term where he led the audit committee and was invaluable in actively interfacing with Governmental Financing Departments. He was a great supporter and we wish him well in his retirement.
Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.
For further information contact:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.